JP2011518819A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011518819A5 JP2011518819A5 JP2011505593A JP2011505593A JP2011518819A5 JP 2011518819 A5 JP2011518819 A5 JP 2011518819A5 JP 2011505593 A JP2011505593 A JP 2011505593A JP 2011505593 A JP2011505593 A JP 2011505593A JP 2011518819 A5 JP2011518819 A5 JP 2011518819A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- nhr
- alkyl
- saturated aliphatic
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 CN*C([C@]1N=C(*)C(*)=C)C=CN=C1N Chemical compound CN*C([C@]1N=C(*)C(*)=C)C=CN=C1N 0.000 description 19
- CJHBCYQLRZBCJD-UHFFFAOYSA-N CC(C)(C)c1n[n](CC=C)c(NC(Nc(cc2)c3ncccc3c2Oc2ccnc(N3)c2N=CC3=O)=O)c1 Chemical compound CC(C)(C)c1n[n](CC=C)c(NC(Nc(cc2)c3ncccc3c2Oc2ccnc(N3)c2N=CC3=O)=O)c1 CJHBCYQLRZBCJD-UHFFFAOYSA-N 0.000 description 2
- BMJIPGXVDYVSGD-UHFFFAOYSA-N CC(C)(C)c(cc1NC(Nc(cc2)c(cccn3)c3c2Oc(ccnc2N3)c2NC3=O)=O)n[n]1-c1ccccc1 Chemical compound CC(C)(C)c(cc1NC(Nc(cc2)c(cccn3)c3c2Oc(ccnc2N3)c2NC3=O)=O)n[n]1-c1ccccc1 BMJIPGXVDYVSGD-UHFFFAOYSA-N 0.000 description 1
- DPBHAHWMWJKZGA-UHFFFAOYSA-N CC(C)(C)c(cc1NC(Nc(cc2)c3ncccc3c2Oc(ccnc2N3)c2N=C(C)C3=O)=O)n[n]1-c1ccc(C)cc1 Chemical compound CC(C)(C)c(cc1NC(Nc(cc2)c3ncccc3c2Oc(ccnc2N3)c2N=C(C)C3=O)=O)n[n]1-c1ccc(C)cc1 DPBHAHWMWJKZGA-UHFFFAOYSA-N 0.000 description 1
- ZCHGTAIGWVCOPK-UHFFFAOYSA-N CC(C)(C)c(cc1NC(Nc(cc2)c3ncccc3c2Oc(ccnc2N3)c2N=CC3=O)=O)n[n]1-c1ccccc1 Chemical compound CC(C)(C)c(cc1NC(Nc(cc2)c3ncccc3c2Oc(ccnc2N3)c2N=CC3=O)=O)n[n]1-c1ccccc1 ZCHGTAIGWVCOPK-UHFFFAOYSA-N 0.000 description 1
- PXVWKAMYEXONBP-UHFFFAOYSA-N CC(C)(C)c(cc1NC(Nc(cc2)c3ncccc3c2Oc(ccnc2N3)c2NC3=O)=O)n[n]1-c1ccccc1 Chemical compound CC(C)(C)c(cc1NC(Nc(cc2)c3ncccc3c2Oc(ccnc2N3)c2NC3=O)=O)n[n]1-c1ccccc1 PXVWKAMYEXONBP-UHFFFAOYSA-N 0.000 description 1
- BXJIDCANXSNGNH-UHFFFAOYSA-N CC(C)(C)c(cc1NC(Nc(cc2)c3ncccc3c2Oc(ccnc2N3C)c2NC3=O)=O)n[n]1-c1ccccc1 Chemical compound CC(C)(C)c(cc1NC(Nc(cc2)c3ncccc3c2Oc(ccnc2N3C)c2NC3=O)=O)n[n]1-c1ccccc1 BXJIDCANXSNGNH-UHFFFAOYSA-N 0.000 description 1
- OQFJAIUUSJZJCS-UHFFFAOYSA-N CC(C)(C)c(cc1NC(Nc(cc2)c3ncccc3c2Oc(ccnc2N3c(ccc4c(cc5)Oc(ccnc6N=C7)c6NC7=O)nc4c5NC(Nc4cc(C(F)(F)F)ccc4F)=O)c2N=C(C)C3=O)=O)n[n]1-c1ccccc1 Chemical compound CC(C)(C)c(cc1NC(Nc(cc2)c3ncccc3c2Oc(ccnc2N3c(ccc4c(cc5)Oc(ccnc6N=C7)c6NC7=O)nc4c5NC(Nc4cc(C(F)(F)F)ccc4F)=O)c2N=C(C)C3=O)=O)n[n]1-c1ccccc1 OQFJAIUUSJZJCS-UHFFFAOYSA-N 0.000 description 1
- KQAFRTUOPPOINF-UHFFFAOYSA-N CC(C)(C)c(cc1NC(Nc(cc2)c3ncccc3c2Oc(ccnc2N=C3)c2NC3=O)=O)n[n]1-c1ccccc1 Chemical compound CC(C)(C)c(cc1NC(Nc(cc2)c3ncccc3c2Oc(ccnc2N=C3)c2NC3=O)=O)n[n]1-c1ccccc1 KQAFRTUOPPOINF-UHFFFAOYSA-N 0.000 description 1
- RYLGLIHUAIAPRD-UHFFFAOYSA-N CC(C)(C)c(cc1NC(Nc(cc2)c3ncccc3c2Oc2ccnc(N3)c2N=CC3=O)=O)n[n]1-c1ccc(C)cc1 Chemical compound CC(C)(C)c(cc1NC(Nc(cc2)c3ncccc3c2Oc2ccnc(N3)c2N=CC3=O)=O)n[n]1-c1ccc(C)cc1 RYLGLIHUAIAPRD-UHFFFAOYSA-N 0.000 description 1
- CXXJYUVMZVPNFO-UHFFFAOYSA-N CC(C)(C)c1cc(NC(Nc(cc2)c3ncccc3c2Oc(ccnc2N3Cc(ccc4c(cc5)Oc(ccnc6N7)c6N=C(C)C7=O)nc4c5NC(Nc4cc(C(F)(F)F)ccc4F)=O)c2NC3=O)=O)ccc1 Chemical compound CC(C)(C)c1cc(NC(Nc(cc2)c3ncccc3c2Oc(ccnc2N3Cc(ccc4c(cc5)Oc(ccnc6N7)c6N=C(C)C7=O)nc4c5NC(Nc4cc(C(F)(F)F)ccc4F)=O)c2NC3=O)=O)ccc1 CXXJYUVMZVPNFO-UHFFFAOYSA-N 0.000 description 1
- CWLVNHSJQRAMGN-UHFFFAOYSA-N CC(C)(C)c1n[n](C)c(NC(Nc(cc2)c3ncccc3c2Oc(ccnc2N3)c2N=C(C)C3=O)=O)c1 Chemical compound CC(C)(C)c1n[n](C)c(NC(Nc(cc2)c3ncccc3c2Oc(ccnc2N3)c2N=C(C)C3=O)=O)c1 CWLVNHSJQRAMGN-UHFFFAOYSA-N 0.000 description 1
- GBLAGKNGZABPAI-UHFFFAOYSA-N CC(C)(C)c1n[n](C)c(NC(Nc(cc2)c3ncccc3c2Oc(ccnc2N3C)c2NC3=O)=O)c1 Chemical compound CC(C)(C)c1n[n](C)c(NC(Nc(cc2)c3ncccc3c2Oc(ccnc2N3C)c2NC3=O)=O)c1 GBLAGKNGZABPAI-UHFFFAOYSA-N 0.000 description 1
- GADIXAOZEUPTNN-UHFFFAOYSA-N CC(C)(C)c1n[n](CC#C)c(NC(Nc(cc2)c3ncccc3c2Oc(ccnc2N3)c2N=C(C)C3=O)=O)c1 Chemical compound CC(C)(C)c1n[n](CC#C)c(NC(Nc(cc2)c3ncccc3c2Oc(ccnc2N3)c2N=C(C)C3=O)=O)c1 GADIXAOZEUPTNN-UHFFFAOYSA-N 0.000 description 1
- PGGVDDPFPVRMFT-UHFFFAOYSA-N CC(C)(C)c1n[n](CC#C)c(NC(Nc(cc2)c3ncccc3c2Oc(ccnc2N3)c2N=CC3=O)=O)c1 Chemical compound CC(C)(C)c1n[n](CC#C)c(NC(Nc(cc2)c3ncccc3c2Oc(ccnc2N3)c2N=CC3=O)=O)c1 PGGVDDPFPVRMFT-UHFFFAOYSA-N 0.000 description 1
- MIWDWEGHFKZMPY-UHFFFAOYSA-N CC(C)(C)c1n[n](CC=C)c(NC(Nc(cc2)c3ncccc3c2Oc(ccnc2N3)c2N=C(C)C3=O)=O)c1 Chemical compound CC(C)(C)c1n[n](CC=C)c(NC(Nc(cc2)c3ncccc3c2Oc(ccnc2N3)c2N=C(C)C3=O)=O)c1 MIWDWEGHFKZMPY-UHFFFAOYSA-N 0.000 description 1
- UMZXCENJRKMTMD-UHFFFAOYSA-N O=C(Cc1cccc(C(F)(F)F)c1)Nc(cc1)c(cccn2)c2c1Oc(ccnc1N2)c1NC2=O Chemical compound O=C(Cc1cccc(C(F)(F)F)c1)Nc(cc1)c(cccn2)c2c1Oc(ccnc1N2)c1NC2=O UMZXCENJRKMTMD-UHFFFAOYSA-N 0.000 description 1
- ZKJOHMNDIPVMQY-UHFFFAOYSA-N O=C(Cc1cccc(OC(F)(F)F)c1)Nc(cc1)c(cccn2)c2c1Oc(ccnc1N2)c1NC2=O Chemical compound O=C(Cc1cccc(OC(F)(F)F)c1)Nc(cc1)c(cccn2)c2c1Oc(ccnc1N2)c1NC2=O ZKJOHMNDIPVMQY-UHFFFAOYSA-N 0.000 description 1
- QCOMGVGQTCJQFN-UHFFFAOYSA-N O=C(Nc(cc1)c(cccn2)c2c1Oc(ccnc1N2)c1NC2=O)Nc1cc(C(F)(F)F)ccc1F Chemical compound O=C(Nc(cc1)c(cccn2)c2c1Oc(ccnc1N2)c1NC2=O)Nc1cc(C(F)(F)F)ccc1F QCOMGVGQTCJQFN-UHFFFAOYSA-N 0.000 description 1
- ZMBODPKMZWUNRC-UHFFFAOYSA-N O=C(Nc(cc1)c2ncccc2c1Oc(ccnc1N2)c1N=CC2=O)Nc1cc(C(F)(F)F)ccc1F Chemical compound O=C(Nc(cc1)c2ncccc2c1Oc(ccnc1N2)c1N=CC2=O)Nc1cc(C(F)(F)F)ccc1F ZMBODPKMZWUNRC-UHFFFAOYSA-N 0.000 description 1
- QOMBDSLLDLQYSB-UHFFFAOYSA-N O=C(Nc(cc1)c2ncccc2c1Oc(ccnc1N2)c1NC2=O)Nc(cc(C(F)(F)F)cc1)c1F Chemical compound O=C(Nc(cc1)c2ncccc2c1Oc(ccnc1N2)c1NC2=O)Nc(cc(C(F)(F)F)cc1)c1F QOMBDSLLDLQYSB-UHFFFAOYSA-N 0.000 description 1
- ZDOYCGYEVDLNMK-UHFFFAOYSA-N O=C(Nc(cc1C(F)(F)F)ccc1Cl)Nc(cc1)c(cccn2)c2c1Oc(ccnc1N2)c1NC2=O Chemical compound O=C(Nc(cc1C(F)(F)F)ccc1Cl)Nc(cc1)c(cccn2)c2c1Oc(ccnc1N2)c1NC2=O ZDOYCGYEVDLNMK-UHFFFAOYSA-N 0.000 description 1
- PLYDJXZQVQHDON-UHFFFAOYSA-N O=C(Nc(cc1C(F)(F)F)ccc1Cl)Nc(cc1)c2ncccc2c1Oc(ccnc1N2)c1NC2=O Chemical compound O=C(Nc(cc1C(F)(F)F)ccc1Cl)Nc(cc1)c2ncccc2c1Oc(ccnc1N2)c1NC2=O PLYDJXZQVQHDON-UHFFFAOYSA-N 0.000 description 1
- NITSFTLBQYEDPT-UHFFFAOYSA-N O=C(Nc1cccc(C(F)(F)F)c1)Nc(cc1)c2ncccc2c1Oc(ccnc1N2)c1NC2=O Chemical compound O=C(Nc1cccc(C(F)(F)F)c1)Nc(cc1)c2ncccc2c1Oc(ccnc1N2)c1NC2=O NITSFTLBQYEDPT-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4790208P | 2008-04-25 | 2008-04-25 | |
| GBGB0807609.3A GB0807609D0 (en) | 2008-04-25 | 2008-04-25 | Therapeutic compounds and their use |
| US61/047,902 | 2008-04-25 | ||
| GB0807609.3 | 2008-04-25 | ||
| PCT/GB2009/001077 WO2009130487A1 (en) | 2008-04-25 | 2009-04-27 | Aryl-quinolyl compounds and their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011518819A JP2011518819A (ja) | 2011-06-30 |
| JP2011518819A5 true JP2011518819A5 (enExample) | 2012-04-26 |
Family
ID=39522596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011505593A Withdrawn JP2011518819A (ja) | 2008-04-25 | 2009-04-27 | アリール−キノリル化合物及びその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8383816B2 (enExample) |
| EP (1) | EP2285805B1 (enExample) |
| JP (1) | JP2011518819A (enExample) |
| CN (1) | CN102066371A (enExample) |
| AU (1) | AU2009239785A1 (enExample) |
| BR (1) | BRPI0911525A2 (enExample) |
| CA (1) | CA2721575A1 (enExample) |
| GB (1) | GB0807609D0 (enExample) |
| WO (1) | WO2009130487A1 (enExample) |
| ZA (1) | ZA201007395B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2229391B1 (en) | 2007-12-19 | 2014-08-06 | Cancer Research Technology Limited | Pyrido[2,3-b]pyrazine-8-substituted compounds and their use |
| WO2009111277A1 (en) * | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Imdizo [4. 5-b] pyridine derivatives used as raf inhibitors |
| EP2265574A1 (en) * | 2008-02-29 | 2010-12-29 | Array Biopharma, Inc. | N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer |
| AR070535A1 (es) * | 2008-02-29 | 2010-04-14 | Array Biopharma Inc | Compuestos inhibidores de raf y metodos para usarlos |
| AU2009222144A1 (en) * | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Pyrazole [3, 4-b] pyridine Raf inhibitors |
| GB0807609D0 (en) | 2008-04-25 | 2008-06-04 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| CA2786834C (en) | 2010-02-01 | 2018-10-16 | Cancer Research Technology Limited | 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy |
| US8933228B2 (en) | 2010-06-17 | 2015-01-13 | Respivert, Ltd. | Respiratory formulations and compounds for use therein |
| SG193301A1 (en) * | 2011-03-09 | 2013-10-30 | Merck Patent Gmbh | Pyrido [2, 3 - b] pyrazine derivatives and their therapeutical uses |
| CA2916543C (en) * | 2013-06-28 | 2023-03-14 | Beigene, Ltd. | Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors |
| GB201320732D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Methods of chemical synthesis |
| GB201320729D0 (en) * | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| EP3575305A1 (fr) | 2018-05-31 | 2019-12-04 | Biocidal Alternative Solutions | Procédé de fabrication de composés comprenant un groupe fonctionnel oxazolopyridinones |
| JOP20180131B1 (ar) * | 2018-12-24 | 2023-03-28 | Univ Of Petra | مركبات الكوينولون المستبدلة واستخدامها في علاج السرطان وطريقة تحضيرها |
| TWI812301B (zh) * | 2021-06-24 | 2023-08-11 | 南韓商Ｌｇ化學股份有限公司 | 作為ｒｏｎ抑制劑之新穎尿素衍生物化合物 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US238568A (en) * | 1881-03-08 | Washing-machine | ||
| JPS5665863A (en) | 1979-10-31 | 1981-06-03 | Tokyo Organ Chem Ind Ltd | Novel aniline derivative, its preparation and pesticide containing the same |
| JPS5738777A (en) | 1980-08-19 | 1982-03-03 | Sogo Yatsukou Kk | 2-sufanilamidopyrathyn derivative |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5643755A (en) | 1994-10-07 | 1997-07-01 | Regeneron Pharmaceuticals Inc. | Nucleic acid encoding tie-2 ligand |
| US5879672A (en) | 1994-10-07 | 1999-03-09 | Regeneron Pharmaceuticals, Inc. | Tie-2 ligand 1 |
| WO1996009381A1 (en) | 1994-09-22 | 1996-03-28 | Helsinki University Licensing Ltd. Oy | Promoter for the receptor tyrosine kinase, tie |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| EP0951541B1 (en) | 1995-07-31 | 2005-11-30 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| ZA971896B (en) | 1996-03-26 | 1998-09-07 | Du Pont Merck Pharma | Aryloxy-and arythio-fused pyridines and pyrimidines and derivatives |
| CA2263479A1 (en) | 1996-09-25 | 1998-04-02 | Zeneca Limited | Quinoline derivatives inhibiting the effect of growth factors such as vegf |
| US6030831A (en) | 1997-09-19 | 2000-02-29 | Genetech, Inc. | Tie ligand homologues |
| CA2305370C (en) | 1997-09-26 | 2006-11-28 | Gerald Mcmahon | Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function |
| GB9721437D0 (en) | 1997-10-10 | 1997-12-10 | Glaxo Group Ltd | Heteroaromatic compounds and their use in medicine |
| GB2356398A (en) | 1999-11-18 | 2001-05-23 | Lilly Dev Ct S A | Preparation of arylsulfamides |
| US6610688B2 (en) | 1999-12-21 | 2003-08-26 | Sugen, Inc. | 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors |
| US6492529B1 (en) | 2000-01-18 | 2002-12-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Bis pyrazole-1H-pyrazole intermediates and their synthesis |
| JP2004517080A (ja) | 2000-11-29 | 2004-06-10 | グラクソ グループ リミテッド | Ｔｉｅ−２および／またはｖｅｇｆｒ−２の阻害剤として有用なベンゾイミダゾール誘導体 |
| JP4643909B2 (ja) | 2001-12-21 | 2011-03-02 | ザ ウェルカム トラスト リミテッド | 遺伝子 |
| EP1534268A4 (en) | 2002-08-09 | 2006-11-02 | Merck & Co Inc | TYROSINE KINASE INHIBITORS |
| TW200538120A (en) | 2004-02-20 | 2005-12-01 | Kirin Brewery | Compound having TGF-beta inhibitory activity and pharmaceutical composition containing same |
| TW200616974A (en) | 2004-07-01 | 2006-06-01 | Astrazeneca Ab | Chemical compounds |
| AU2005278959A1 (en) | 2004-08-31 | 2006-03-09 | Astrazeneca Ab | Quinazolinone derivatives and their use as B-Raf inhibitors |
| GB0423554D0 (en) * | 2004-10-22 | 2004-11-24 | Cancer Rec Tech Ltd | Therapeutic compounds |
| GB0428082D0 (en) | 2004-12-22 | 2005-01-26 | Welcome Trust The Ltd | Therapeutic compounds |
| EP1957460A1 (en) | 2005-12-08 | 2008-08-20 | Millennium Pharmaceuticals, Inc. | Bicyclic compounds with kinase inhibitory activity |
| US7989461B2 (en) | 2005-12-23 | 2011-08-02 | Amgen Inc. | Substituted quinazolinamine compounds for the treatment of cancer |
| EP2013207B1 (en) | 2006-04-26 | 2012-04-25 | Cancer Research Technology Limited | Imidazo[4,5-b]pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds |
| WO2008044688A1 (en) * | 2006-10-11 | 2008-04-17 | Daiichi Sankyo Company, Limited | Urea derivative |
| EP2229391B1 (en) | 2007-12-19 | 2014-08-06 | Cancer Research Technology Limited | Pyrido[2,3-b]pyrazine-8-substituted compounds and their use |
| GB0807609D0 (en) | 2008-04-25 | 2008-06-04 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| CA2786834C (en) | 2010-02-01 | 2018-10-16 | Cancer Research Technology Limited | 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy |
-
2008
- 2008-04-25 GB GBGB0807609.3A patent/GB0807609D0/en not_active Ceased
-
2009
- 2009-04-27 CA CA2721575A patent/CA2721575A1/en not_active Abandoned
- 2009-04-27 AU AU2009239785A patent/AU2009239785A1/en not_active Abandoned
- 2009-04-27 JP JP2011505593A patent/JP2011518819A/ja not_active Withdrawn
- 2009-04-27 US US12/988,619 patent/US8383816B2/en not_active Expired - Fee Related
- 2009-04-27 WO PCT/GB2009/001077 patent/WO2009130487A1/en not_active Ceased
- 2009-04-27 CN CN2009801234973A patent/CN102066371A/zh active Pending
- 2009-04-27 BR BRPI0911525-0A patent/BRPI0911525A2/pt not_active IP Right Cessation
- 2009-04-27 EP EP09734443.6A patent/EP2285805B1/en active Active
-
2010
- 2010-10-15 ZA ZA2010/07395A patent/ZA201007395B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011518819A5 (enExample) | ||
| RU2521333C2 (ru) | Способы и композиции для стимулирования нейрогенеза и ингибирования дегенерации нейронов с использованием изотиазолопиримидинонов | |
| RU2008109914A (ru) | Применение производных тиенопиридона в качестве активаторов амфк и фармацевтические композиции, которые их содержат | |
| BR0110548A (pt) | Composto, processo para a preparação do mesmo, composição farmacêutica, método de tratamento de distúrbios mediados pelo receptor de neuropeptìdio y5 em um animal de sangue quente, método de tratamento de distúrbios da alimentação em um animal de sangue quente, método para promover perda de peso em um animal de sangue quente, e, uso de um composto ou de um seu sal, prodroga ou solvato farmacêuticamente aceitável | |
| KR20210075992A (ko) | Sting 작동 화합물 | |
| JP2021152063A5 (enExample) | ||
| BR112020014169A2 (pt) | Compostos de benzamida | |
| JP2006504766A5 (enExample) | ||
| CN105753905A (zh) | 新的化合物以及用于治疗的方法 | |
| WO2017180769A1 (en) | Small molecules for immunogenic treatment of cancer | |
| AU2018264116B2 (en) | Novel compounds for treating parasitic disease | |
| AU2008213576A1 (en) | Treatment of resistant or refractory cancers with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin | |
| ES2974212T3 (es) | Derivados de mononucleótidos de nicotinamida en el tratamiento y la prevención de la enfermedad de células falciformes | |
| RU2017103148A (ru) | Производные 2-амино-бензимидазола и их использование в качестве ингибиторов 5-липоксигеназы и/или простагландин е-синтазы | |
| JPH05502872A (ja) | 医薬 | |
| RU99127433A (ru) | Эрголиновые производные и их применение в качестве антагонистов рецепторов соматостатина | |
| MX2007005857A (es) | Inhibidores de cinasa. | |
| CA3148211A1 (en) | Aryl sulfonamides as small molecule stat3 inhibitors | |
| JP2007515476A5 (enExample) | ||
| ES2825798T3 (es) | Moduladores de canales de Ca2+ activados por liberación de Ca2+ (CRAC) y usos farmacéuticos de los mismos | |
| JP7734663B2 (ja) | カスパーゼ６阻害剤およびその使用 | |
| RU2004110042A (ru) | Тиено[2,3-d] пиримидины с комбинированной агонистической активностью lh и fsh | |
| KR20080016926A (ko) | 신경 재생 및/또는 보호제 | |
| JP2002534390A (ja) | 癌治療におけるアデノシンアゴニスト類の使用 | |
| ES2587064T3 (es) | Sales fumarato novedosas de un antagonista del receptor de histamina H3 |